학술논문
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Document Type
article
Author
Luis M. A. Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A. Lashuel; David Sulzer; Kostas Vekrellis; Glenda M. Halliday; Julianna J. Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D. Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F. Outeiro
Source
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-23 (2021)
Subject
Language
English
ISSN
2373-8057
Abstract
Abstract With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.